Recro Pharma Inc (NASDAQ:REPH) major shareholder Scp Vitalife Partners (Israel) sold 12,964 shares of the stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $8.88, for a total value of $115,120.32. Following the completion of the sale, the insider now directly owns 734,269 shares in the company, valued at $6,520,308.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Scp Vitalife Partners (Israel) also recently made the following trade(s):

  • On Friday, December 28th, Scp Vitalife Partners (Israel) sold 1,980 shares of Recro Pharma stock. The stock was sold at an average price of $9.44, for a total value of $18,691.20.

Shares of Recro Pharma Inc (NASDAQ:REPH) traded up $0.02 during midday trading on Friday, reaching $8.78. The company’s stock had a trading volume of 139,300 shares, compared to its average volume of 209,567. Recro Pharma Inc has a 1 year low of $5.81 and a 1 year high of $10.59. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.59 and a quick ratio of 1.35. The firm has a market capitalization of $167.91, a price-to-earnings ratio of -4.08 and a beta of -0.50.

REPH has been the topic of several analyst reports. Zacks Investment Research lowered Recro Pharma from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $11.00 target price on shares of Recro Pharma in a research report on Friday, October 27th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $11.65.

A number of hedge funds and other institutional investors have recently modified their holdings of REPH. Schwab Charles Investment Management Inc. acquired a new position in shares of Recro Pharma during the second quarter valued at $215,000. Bank of New York Mellon Corp increased its holdings in shares of Recro Pharma by 182.7% during the second quarter. Bank of New York Mellon Corp now owns 50,532 shares of the specialty pharmaceutical company’s stock valued at $355,000 after purchasing an additional 32,655 shares during the period. Teachers Advisors LLC acquired a new position in shares of Recro Pharma during the second quarter valued at $162,000. TIAA CREF Investment Management LLC acquired a new position in shares of Recro Pharma during the second quarter valued at $249,000. Finally, Northern Trust Corp increased its holdings in shares of Recro Pharma by 428.5% during the second quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock valued at $1,254,000 after purchasing an additional 144,676 shares during the period. 61.55% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Recro Pharma Inc (REPH) Major Shareholder Scp Vitalife Partners (Israel) Sells 12,964 Shares of Stock” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2018/01/05/recro-pharma-inc-reph-major-shareholder-scp-vitalife-partners-israel-sells-12964-shares-of-stock.html.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Insider Buying and Selling by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.